Myriad Genetics Inc (MYGN)
Healthcare
Diagnostics & Research
3.00 $
+5.6%
vs. previous close
Closing price · As of: 3. Aug 2026
Myriad Genetics Inc (MYGN) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 191 million $. Tick rows to compare them in a chart.
| Tick rows to compare them in a chart (up to 4) | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 192 | 197 | 202 | 212 | 213 | 211 | 196 | 213 | 206 | 210 | 200 | 191 | 807 | |
| 58 | 62 | 65 | 64 | 64 | 60 | 62 | 61 | 62 | 63 | 63 | 64 | 251 | |
| 134 | 135 | 138 | 147 | 150 | 151 | 134 | 152 | 144 | 147 | 138 | 127 | 555 | |
| 24 | 21 | 25 | 27 | 29 | 32 | 28 | 26 | 28 | 26 | 27 | 25 | 106 | |
| 136 | 33 | 71 | 72 | 139 | 148 | 67 | 67 | 68 | 56 | 62 | 58 | 244 | |
| 194 | 166 | 166 | 184 | 170 | 190 | 163 | 481 | 167 | 153 | 163 | 166 | 648 | |
| -60 | -31 | -28 | -37 | -20 | -39 | -29 | -329 | -23 | -5.7 | -25 | -39 | -93 | |
| 1.0 | 0.9 | 0.5 | 0.8 | 0.8 | 0.7 | 0.8 | 1.5 | 3.8 | 4.4 | 4.1 | -4.1 | 8.2 | |
| -61 | -32 | -26 | -37 | -21 | -39 | -29 | -331 | -26 | -8.9 | -34 | -43 | -112 | |
| 0.1 | -1.1 | 0.1 | -0.5 | 0.9 | 3.4 | -29 | -0.1 | 1.2 | -1.0 | – | 0.6 | – | |
| -61 | -31 | -26 | -37 | -22 | -43 | -0.1 | -331 | -27 | -7.9 | -34 | -43 | -113 | |
| -46 | -16 | -9.7 | -21 | -4.8 | -24 | -14 | -315 | -9.8 | 8.1 | -18 | -39 | -58 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.